150 mg 30ct
Venlafaxine Hydrochloride Tablet, Extended Release
Product Images NDC 72865-200
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 72865-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
150 mg 90ct
XLcare is a medication containing Venlafaxine Extended-Release Tablets. Each tablet contains 150mg Venlafaxine hydrochloride. The usual dosage is once daily and a medication guide will be provided with each bottle. It is recommended to be stored at 25°C (77°F) with excursions permitted to 15° - 30°C (59° - 86°F) and protected from moisture and humidity. Manufactured by Ascent Pharmaceuticals, it is distributed by XLCare Pharmaceuticals.*
225 mg 30ct
XLcare Venlafaxine is an extended-release tablet containing 225mg of Venlafaxine hydrochloride. It is prescribed for use once a day and comes with an attached Medication Guide. The tablets should be stored at 25°C (77°F) with excursions permitted to 15° - 30°C (59° - 86°F). The medication should be protected from moisture and humidity. XLcare Venlafaxine is manufactured by Ascent Pharmaceuticals and is distributed by XLCare Pharmaceuticals. Please see the package insert for dosage information.*
225 mg 90ct
XLcare is a pharmaceutical company that produces Venlafaxine Extended-Release Tablets with NDC code 72865-200-20. The medication is RX-only and is usual to be taken once a day following the dosage information provided in the package insert. It is recommended to store the tablets at a temperature between 15°C-30°C (59°F-86°F) and protect them from moisture and humidity. The tablets contain 225mg of venlafaxine hydrochloride, in the quantity of 90 tablets per package, and are manufactured by Ascent Pharmaceuticals, Inc. based in Central Islip, New York, for XLCare Pharmaceuticals, Inc., headquartered in Lawrenceville, Georgia.*
37.5 mg 30 Ct
37.5 mg 90ct
75 mg 30ct
XLcare is a medication containing Venlafaxine, and is an extended-release tablet used for treatment. The dosage is once daily and the medication guide should be attached. The tablets come in a bottle of 30 and should be stored at an average room temperature of 25 °C. The medication should be protected against moisture and humidity during storage. XLcare is manufactured by Ascent Pharmaceuticals in Central Isip, NY for XLCare Pharmaceuticals, Inc.*
75 mg 90ct
XLcare is a medication with Venlafaxine extended-release tablets. Each extended-release tablet contains venlafaxine hydrochloride, USP equivalent to 75 mg venlafaxine. It is advised that the authorized dispenser should provide the patient with the attached medication guide for this drug. The usual dosage for Venlafaxine extended-release tablets is once a day as mentioned in the package insert for dosage information. Store the medication at 25°C (77°F) excursions permitted to 15° - 30°C (59° - 86°F) (see USP Controlled Room Temperature). Manufactured by Ascent Pharmaceuticals, Centralsip, NY 11722, and Manufactured for XLcare Pharmaceuticals, Inc., 242 South Culte Street, Suite 202, Lawrenceville, A 30045.*
Symptoms Med Guide
This text appears to be a list of symptoms associated with mental health conditions such as depression, anxiety, and mania. It includes warning signs of suicidal ideation and dangerous impulses, behavior changes such as increased activity and talking, and visual problems. It also mentions other changes in behavior or mood such as extreme agitation, panic attacks, insomnia, irritability, aggression, anger or violence. This text may be useful for individuals seeking a general understanding of the symptoms associated with mental health conditions, but it is not a substitute for seeking professional medical advice.*
Tab-1 (Tab 1)
Tab 2 And 3
Table 2 shows the number and percentage of sustained elevations in SDBP in Venlafaxine Hydrochloride Extended-Release Capsule Premarketing studies, classified by indication. Table 3 depicts the incidence percentage of sustained elevations in SDBP for Venlafaxine Hydrochloride Immediate-Release Tablet studies, depending on the daily dosage.*
Tab-4 (Tab 4)
Tab-5 (Tab 5)
This text provides information on the incidence of insomnia and nervousness in trials for major depressive disorder and other conditions, comparing the effects of Venlafaxine Hydrochloride extended-release capsules versus a placebo. In individuals with major depressive disorder who received Venlafaxine Hydrochloride, 17% reported experiencing insomnia, compared to 1% in the placebo group, while 10% reported nervousness, compared to 5% in the placebo group. In other trials, including those for non-depressive disorders, Venlafaxine Hydrochloride was associated with insomnia in 24% of participants and nervousness in 10%. The placebo group in these trials had a lower incidence of these symptoms.*
Struct
Tab 6
Tab 7
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
